India’s weight-loss drug boom and the risks behind it

Written by

in

Soutik BiswasIndia correspondent

Reuters FILE PHOTO: Vials of Eli Lilly's Mounjaro, a tirzepatide injection drug used for treating type 2 diabetes and weight loss, are seen in a fridge at a health clinic in Hyderabad, India, April 14, 2025. REUTERS/Almaas Masood/File Photo — India’s anti-obesity drug market has seen a sixfold jump in five years

The calls come thick and fast to Mumbai-based diabetologist Rahul Baxi – but not just from patients struggling to control blood sugar.

Continue Reading

More posts

WFP says food aid reached 1M people in Gaza but far more access needed – Middle East Monitor

November 4, 2025
With historic medal haul, Iranian girls steal limelight at 2025 Asian Youth Games

November 4, 2025
Security threat halts flights at Reagan National Airport

November 4, 2025
Araghchi blasts granting Nobel peace prize to a warmonger

November 4, 2025